Compare Novavax Inc (NVAX) vs TKO Group Holdings Inc (TKO) Price & Performance

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

TKO trades at $195.15, up 3.03% today, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The stock shows robust revenue growth, with Q2 2026 revenue reaching $1.55 billion (up 18% year-over-year, Business Wire, August 3, 2026), and raised full-year guidance. However, a high P/E ratio of 68.33 and mixed quarterly EPS results highlight valuation concerns amid solid operational performance.

The outlook remains positive due to strong media rights and live event momentum, but risks include earnings volatility and competitive pressures. Analyst consensus is strongly bullish with a $228.17 price target, suggesting ~17% upside potential from current levels.